methylene blue bpc 157 BPC-157 – Alphaceuticals by Dr. Catherine BPC-157, TB-500 Blend – Nordsci

NAD+ and methyl donor research

Slowing the ramp to the label cadence (2.5 mg start, 2.5 mg steps, four-week holds) dropped that to mid-single digits at every maintenance dose, at no cost to the 12-week result, and the dedicated slow-titration trial reached placebo range. Reaching 15 mg is not the problem

This was published 12 years ago Much ado about nothing: the peptide they say never worked There is much confusion about the significance of the banned peptide at the centre of the AFL doping scandal - and perhaps that is not so surprising

Contraindications Based on mechanism of action and conservative interpretation of potential risks, BPC-157 use is generally discouraged in individuals with active or recent cancer, pregnancy or breastfeeding, autoimmune conditions with active flares, children and adolescents (unknown effects on development), and known hypersensitivity to any peptide compounds